Conduit Pharmaceuticals Inc.

NASDAQ CDT
$1.18 -0.0100 -0.84%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
31.90M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-227.10M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
40.84M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-82.90 %

Upcoming events Conduit Pharmaceuticals Inc.

All events
No upcoming events scheduled

Stock chart Conduit Pharmaceuticals Inc.

Stock analysis Conduit Pharmaceuticals Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.64 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-41.95 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
13.10 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
14.94 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-1.59 -50.00

Price change Conduit Pharmaceuticals Inc. per year

0.38$ 14.30$
Min Max

Summary analysis Conduit Pharmaceuticals Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Conduit Pharmaceuticals Inc.

Revenue and net income Conduit Pharmaceuticals Inc.

All parameters

About company Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Address:
4995 Murphy Canyon Road, San Diego, CA, United States, 92123
Company name: Conduit Pharmaceuticals Inc.
Issuer ticker: CDT
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2023-09-25
Sector: Healthcare
Industry: Biotechnology
Site: https://www.conduitpharma.com